NCT01109056

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 115 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).

Conditions

• Pterygium

Interventions

Type	Name	Description
DRUG	cyclosporine ophthalmic emulsion 0.05%	One drop in the study eye (or eyes) administered four times daily (QID)
DRUG	Vehicle	One drop in the study eye (or eyes) administered four times daily (QID)

Timeline

• Start date: 2010-06-01
• Primary completion: 2011-05-01
• Completion: 2011-06-01
• First posted: 2010-04-22
• Last updated: 2012-06-25
• Results posted: 2012-06-25

Locations

3 sites across 3 countries: United States, Australia, Singapore